IDH1 and central nervous system cancer: Therefore, it is critical to uncover the molecular mechanisms underlying glioma development and progression, and classification such as IDH status, ATRX/TERT, 1p/19q codeletion, histone gene mutations, which could reveal novel biomarkers and support the development of therapeutic strategies for patients with glioma.